Weed (BUDZ) Income from Continuing Operations (2010 - 2026)
Weed (BUDZ) recorded quarterly Income from Continuing Operations of 175256.0 in Q1 2026, up 76.64% quarter-over-quarter from 750188.0 in Q4 2025, and up 60.21% on a YoY basis from 109391.26 in Q1 2025.
Weed (BUDZ) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Weed's Income from Continuing Operations history runs 13 years deep, the most recent figure standing at 175256.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 60.21% year-over-year to 175256.0; the TTM figure through Mar 2026 stood at 1107006.0 (down 41.83% YoY), while the FY2025 annual figure was 1372206.0, down 168.68% from the prior year.
- Income from Continuing Operations was 175256.0 for Q1 2026 at Weed, up from 750188.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 768714.0 in Q4 2023 to a low of 750188.0 in Q4 2025.
- Historically, Income from Continuing Operations has averaged 208026.18 across 5 years, with a median of 175256.0 in 2026.
- The sharpest annual moves came in 2023 and 2025: Income from Continuing Operations soared 348.42% in 2023, then slumped 463.1% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 309436.0 in 2022, then surged by 348.42% to 768714.0 in 2023, then slumped by 117.33% to 133224.0 in 2024, then plunged by 463.1% to 750188.0 in 2025, then soared by 76.64% to 175256.0 in 2026.
- The last three Income from Continuing Operations figures came in at 175256.0 (Q1 2026), 750188.0 (Q4 2025), and 73946.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 370.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 21.05 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -92.12 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 118.42 Mn |
| 10 | Weed | - | - | - | -175,256.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -175,256.00 |
| Dec 31, 2025 | -750,188.00 |
| Sep 30, 2025 | -73,946.00 |
| Jun 30, 2025 | -107,616.00 |
| Mar 31, 2025 | -440,455.00 |
| Dec 31, 2024 | -133,224.00 |
| Sep 30, 2024 | -95,887.00 |
| Jun 30, 2024 | -110,953.00 |
| Mar 31, 2024 | -170,652.00 |
| Dec 31, 2023 | 768,714.00 |
| Sep 30, 2023 | -254,127.00 |
| Jun 30, 2023 | -173,443.00 |
| Mar 31, 2023 | -197,014.00 |
| Dec 31, 2022 | -309,436.00 |
| Sep 30, 2022 | -308,990.00 |
| Jun 30, 2022 | -426,751.00 |
| Mar 31, 2022 | -577,221.00 |
| Dec 31, 2021 | -447,639.00 |
| Sep 30, 2021 | -173,325.00 |
| Jun 30, 2021 | -1.22 Mn |